Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

Albert Einstein College of Medicine

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Type 2 Diabetes

Treatments: Drug: glucagon like peptide-1; Dietary Supplement: glucose control

Study type: Interventional

Funder types: Other; Industry; NIH

Identifiers

NCT00609154

1999-041, Sub-study #4

Sub-study 4

R01DK061644-09 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on maintaining the function and health of the insulin producing beta cells. This hormone is known to increase the production rate of new insulin as well as increase the release of insulin into the blood.

Full description

We will measure the rate of new insulin production in subjects with Type 2 diabetes compared to non diabetic subjects. We hypothesize that subjects with Type 2 diabetes make less insulin in response to GLP-1 compared to non diabetic subjects.

Enrollment: 20 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Type 2 Diabetes
• Non diabetic

Exclusion criteria

• Currently taking medication such as thiazolidinediones, metformin, Exenatide, or sitagliptin
• Chronic condition such as chronic heart failure CHF), Coronary Artery Disease (CAD), or chronic renal failure (CRF)
• Anemia

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

Diabetic Group

Experimental group

Description:

Participants with Type 2 diabetes

Treatment:

Dietary Supplement: glucose control

Drug: glucagon like peptide-1

Non-diabetic Group

Active Comparator group

Description:

Participants who are non-diabetic will serve as control. treatment is matched to experimental group

Treatment:

Dietary Supplement: glucose control

Drug: glucagon like peptide-1